88,200 research outputs found
d'Uytrusting der Engelze Maatschappye onder den Generaal James Lancaster voor d'Eerste maal over Zee na d'Oost-Indien gedaan [cartographic material] /
No full text"Premier voyage par mer fait aux Indies Orientales, sous le General James Lancaster aux depens de la Compagnie Angloise, dresse sur les memoires, et rendu plus parfait par diverses observations posterieures, presentement mis en lumiere par Pierre vander Aa ..." [caption]; From : De Wijd-Beroemde voyagien na Oost-en West-Indien ... door Pieter vander Aa.; Map of the Indian Ocean, Asia, East Indies, and including E. Coast of Africa and N. coast of Australia. Relief shown pictorially.; Ms. annotation [pl.] 21.; Scale in Milliaria Germanica and Milliaria Gallica.; Title in cartouche with vignette.; Nordenskiold, 316.; Tooley, 1580.; Also available in an electronic version via the Internet at: http://nla.gov.au/nla.map-nk1571; Rex Nan Kivell Collection Map NK 1571.; T1580 is an uncoloured version of map
Natural history and outcome in systemic AA amyloidosis
No full textBACKGROUND:Deposition of amyloid fibrils derived from circulating acute-phase reactant serum amyloid A protein (SAA) causes systemic AA amyloidosis, a serious complication of many chronic inflammatory disorders. Little is known about the natural history of AA amyloidosis or its response to treatment.METHODS:We evaluated clinical features, organ function, and survival among 374 patients with AA amyloidosis who were followed for a median of 86 months. The SAA concentration was measured serially, and the amyloid burden was estimated with the use of whole-body serum amyloid P component scintigraphy. Therapy for inflammatory diseases was administered to suppress the production of SAA.RESULTS:Median survival after diagnosis was 133 months; renal dysfunction was the predominant disease manifestation. Mortality, amyloid burden, and renal prognosis all significantly correlated with the SAA concentration during follow-up. The risk of death was 17.7 times as high among patients with SAA concentrations in the highest eighth, or octile, (greater/equal 155 mg per liter) as among those with concentrations in the lowest octile (< 4 mg per liter); and the risk of death was four times as high in the next-to-lowest octile (4 to 9 mg per liter). The median SAA concentration during follow-up was 6 mg per liter in patients in whom renal function improved and 28 mg per liter in those in whom it deteriorated (P < 0.001). Amyloid deposits regressed in 60% of patients who had a median SAA concentration of less than 10 mg per liter, and survival among these patients was superior to survival among those in whom amyloid deposits did not regress (P=0.04).CONCLUSIONS:The effects of renal dysfunction dominate the course of AA amyloidosis, which is associated with a relatively favorable outcome in patients with SAA concentrations that remain in the low-normal range (< 4 mg per liter)
Eprodisate for the treatment of renal disease in AA amyloidosis
No full textBackground: Amyloid A (AA) amyloidosis is a complication of chronic inflammatory conditions that develops when proteolytic fragments of serum amyloid A protein (SAA) are deposited in tissues as amyloid fibrils. Amyloid deposition in the kidney causes progressive deterioration in renal function. Eprodisate is a member of a new class of compounds designed to interfere with interactions between amyloidogenic proteins and glycosaminoglycans and thereby inhibit polymerization of amyloid fibrils and deposition of the fibrils in tissues.
Methods: We performed a multicenter, randomized, double-blind, placebo-controlled trial to evaluate the efficacy and safety of eprodisate in patients with AA amyloidosis and kidney involvement. We randomly assigned 183 patients from 27 centers to receive eprodisate or placebo for 24 months. The primary composite end point was an assessment of renal function or death. Disease was classified as worsened if any one of the following occurred: doubling of the serum creatinine level, reduction in creatinine clearance by 50% or more, progression to end-stage renal disease, or death.
Results: At 24 months, disease was worsened in 24 of 89 patients who received eprodisate (27%) and 38 of 94 patients given placebo (40%, P=0.06); the hazard ratio for worsening disease with eprodisate treatment was 0.58 (95% confidence interval, 0.37 to 0.93; P=0.02). The mean rates of decline in creatinine clearance were 10.9 and 15.6 ml per minute per 1.73 m2 of body-surface area per year in the eprodisate and the placebo groups, respectively (P=0.02). The drug had no significant effect on progression to end-stage renal disease (hazard ratio, 0.54; P=0.20) or risk of death (hazard ratio, 0.95; P=0.94). The incidence of adverse events was similar in the two groups.
Conclusions: Eprodisate slows the decline of renal function in AA amyloidosis
Renal AA-amyloidosis in intravenous drug users - a role for HIV-infection?
No full textBackground: Chronic renal disease is a serious complication of long-term intravenous drug use (IVDU). Recent reports have postulated a changing pattern of underlying nephropathy over the last decades.
Methods: Retrospective investigation including all patients with prior or present IVDU that underwent renal biopsy because of chronic kidney disease between 01.04.2002 and 31.03.2012 in the city of Frankfurt/Main, Germany.
Results: Twenty four patients with IVDU underwent renal biopsy because of progressive chronic kidney disease or proteinuria. Renal AA-amyloidosis was the predominant cause of renal failure in 50% of patients. Membranoproliferative glomerulonephritis (GN) was the second most common cause found in 21%. Patients with AA-amyloidosis were more likely to be HIV infected (67 vs.17%; p=0.036) and tended to have a higher rate of repeated systemic infections (92 vs. 50%; p=0.069). Patients with AA-amyloidosis presented with progressive renal disease and nephrotic-range proteinuria but most patients had no peripheral edema or systemic hypertension. Development of proteinuria preceded the decline of GFR for approximately 1--2 years.
Conclusions: AA-amyloidosis was the predominant cause of progressive renal disease in the last 10 years in patients with IVDU. The highest rate of AA-amyloidosis observed was seen in HIV infected patients with IVDU. We speculate that chronic HIV-infection as well as the associated immunosuppression might promote development of AA-amyloidosis by increasing frequency and duration of infections acquired by IVDU
ROTATIONAL ANALYSIS OF THE 6125 \AA \ REGION
No full text C. G. Stevens and R. N, Zare, J. Mol. Spectrosc. 56, 167 (1975). R. E. Smalley, L. Wharton, and D. H. Levy, J. Chem. Phys. 63, 4977 (1975).Author Institution: Department of Chemistry, Columbia University; Department of Chemistry, Columbia University, New yorkThe 6125 \AA \ region wag chosed for investigation, because of the strength of the transitions and because of the seeming simplicity of this region. From an analysis of the rotationally resolved fluorescence of excited by a narrow band (0.03 \AA) \ tunable dye quantum numbers have been assigned to 150 transitions in the 6125 \AA \ region. Four vibronic bands are observed in a 20 \AA \ interval, two of which have been previously A rotational analysis of the 6125 \AA \ and 6126 \AA \ bands is presented, while the small number of transitions assigned to the 6117 \AA \ and 6119 \AA \ bands precludes analysis
COMMERCIAL 584\AA PHOTOELECTRON SPECTROMETER
No full textAuthor Institution: Perkin-Elmer LimitedThe design of a commercial 584\AA Photcelectron Spectrometer will be discussed together with some recent research problems investigated by this technique
Association between AA-NAT gene polymorphism and reproductive performance in sheep
No full textAbstract Arylalkylamine N-acetyltransferase (AA-NAT) is critical enzyme
in Melatonin (MLT) biosynthesis for MLT regulating the animal seasonal
breeding. In this study, DNA sequencing methods were applied to detect
the polymorphisms of the AA-NAT gene in 179 Chinese sheep belonging to
two non-seasonal reproduction breeds and two seasonal reproduction
breeds. One mutation at exon 3 (NM_001009461:c.486A > G) was firstly
described at the sheep AA-NAT locus. Hence, we described the SmaI
PCR-RFLP method for detecting EX3 486A > G mutation, frequencies of
the AA-NAT-G allele varied from 0.871 to 0.908 in two non-seasonal
reproduction breeds and 0.517 to 0.578 in two seasonal reproduction
breeds. The associations of SmaI polymorphism with estrus traits was
analyzed in non-seasonal reproduction breeds sheep and seasonal
reproduction breeds sheep, the significant statistical results were
found between them, the GG genotype frequencies was higher in
non-seasonal reproduction breeds (p < 0.001), while, the GA genotype
frequencies was higher in seasonal reproduction breeds (p < 0.05).
Hence, the EX3 486A > G mutation could facilitate association
analysis and serve as a genetic marker for Chinese sheep breeding and
genetics
SPECTROSCOPIC STUDY OF THE 6111 \AA BAND OF
No full textCharles G. Stevens and Richard N. Zare, J. Mol. Spectrosc, (accepted for publication).""Author Institution: Department of Chemistry, Columbia University, New YorkLaser-induced fluorescence has been used to rotationally analyze Che 6111 {\AA} vibrational band of vapor phase . P, Q, and R branches have been observed and assigned. Rotational constants similar to the 5935 {\AA} have been obtained. Perturbations have been detected through lifetime measurements of individual rotational lines under ``collision-free” conditions ( 1 mTorr pressure)
Biochemical parameters of normal (N), aristocholochic acid (AA), and aristocholochic acid + prednisolone (AA+P) groups.
No full textBiochemical parameters of normal (N), aristocholochic acid (AA), and aristocholochic acid + prednisolone (AA+P) groups.</p
Comparison of glycolysis-related proteins among the N, AA, and AA+P groups on day 14.
No full textComparison of glycolysis-related proteins among the N, AA, and AA+P groups on day 14.</p
- …
